subject have be maintain on a stable dose of levetiracetam lev and a sodium channel block antiepileptic drug scb-aed for at least 4 week prior to the screening visit visit 1 and during the 4-week prospective seizure baseline with or without additional concurrent stable vagal nerve stimulation vns the vns must have be in place for at least 6 month prior to the screening visit visit 1 with constant setting for at least 4-weeks prior to the screening visit visit 1 and throughout the duration of the study 